ethyl [(dimethylamino)methylene]hydrazine carboxylate | 112559-76-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: ethyl [(dimethylamino)methylene]hydrazine carboxylate
• 英文别名: [(dimethylamino)methylene]hydrazine-carboxylic acid ethyl ester；Ethyl 2-[(dimethylamino)methylene]hydrazinecarboxylate；ethyl N-(dimethylaminomethylideneamino)carbamate
• CAS: 112559-76-9
• 化学式: C₆H₁₃N₃O₂
• 分子量: 159.188
• InChiKey: ZPBXXAOTVUNYOA-UHFFFAOYSA-N

物化性质

• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  53.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl [(dimethylamino)methylene]hydrazine carboxylate 、 4-amino-1-(2-methyl-cinnamyl)piperidine 以 乙腈 为溶剂， 反应 0.33h， 以94%的产率得到4-[1-[(E)-2-methyl-3-phenylprop-2-enyl]piperidin-4-yl]-1H-1,2,4-triazol-5-one
  参考文献：
  名称：

  WO2006/67139

  摘要：

  公开号：

文献信息

• [EN] MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES<br/>[FR] PIPERIDINES D'ARYLE OU PIPERAZINES SUBSTITUEES PAR DES HETEROCYCLES A 5 RAMIFICATIONS INHIBANT LA MTP
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005085226A1

  公开（公告）日：2005-09-15

  The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes (Formula (I)). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hyper­triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.

  本发明涉及新颖的芳基哌啶或哌嗪化合物，其被某些含有apoB分泌/MTP抑制活性和伴随的降脂活性的5-成员杂环取代。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗高脂血症、肥胖症和2型糖尿病的药物的用途（公式（I））。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗动脉粥样硬化、胰腺炎、肥胖症、高甘油三酯血症、高胆固醇血症、高脂血症、糖尿病和2型糖尿病的药物的用途。
• Ester and carbamate derivatives of azolones
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05710156A1

  公开（公告）日：1998-01-20

  The invention is concerned with the compounds having the formula ##STR1## the pharmaceutically acceptable acid addition salts and the stereochemically isomeric form thereof, wherein X and Y are CH or N; R.sup.1, R.sup.2 and R.sup.3 are hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 are hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkyloxy, hydroxy, trifluoromethyl, trifluoromethyloxy or difluoromethyloxy; R.sup.6 is C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.1-4 alkyloxyC.sub.1-6 alkyl, phenyl or phenylC.sub.1-4 alkyl; Z is C.dbd.O or CHOH; and ##STR2## compositions comprising said compounds, processes for preparing the same and the use of these compounds for treating Helicobacter related diseases.

  本发明涉及具有以下式子的化合物，其药学上可接受的酸盐和立体化学异构体，其中X和Y为CH或N；R1、R2和R3为氢或C1-4烷基；R4和R5为氢、卤素、C1-4烷基、C1-4烷氧基、羟基、三氟甲基、三氟甲氧基或二氟甲氧基；R6为C1-6烷基、羟基C1-6烷基、C1-4烷氧基C1-6烷基、苯基或苯基C1-4烷基；Z为C=O或CHOH；以及包含上述化合物的组合物，制备这些化合物的过程以及将这些化合物用于治疗幽门螺杆菌相关疾病的用途。
• WO2008/148840
  申请人：——

  公开号：——

  公开（公告）日：——